ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,720,000 ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...

Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $16.9 which represents a decrease of $-1.00 or -5.59% from the prior close of $17.9. The stock opened at $18.15 and touched a ...

"Acadia submits MAA to EMA for Rett syndrome therapy" was originally created and published by Pharmaceutical Technology, a ...

The market didn't like what this stock had to say this morning... The post Why did this $1.4 billion ASX 200 healthcare stock ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) and keeping the price ...